Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in Front-Line Treatment for Newly Diagnosed Stage IIB-IV Epithelial Ovarian Cancer
Findings from the AGO-OVAR 17 BOOST study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC
Evidence for efficacy is based on the results from the POSEIDON study
Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients with Metastatic NSCLC
Findings from the POSEIDON study
EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
New indication concerns the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen
High Frequency of Germline ATM Variants in CLL
Chronic lymphocytic leukaemia that develops in patients with rare germline ATM variants is more likely to have 11q deletion
EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord
It is a generic of Mozobil which has been authorised in the EU since 2009
Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Unresectable Melanoma
Findings from the DREAMseq study
Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and Survival in Locally Advanced Squamous Cell Carcinoma of Head and Neck Unfit for Cisplatin
PembroRad shows less toxicity from standard of care regimen in unfit patients
FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies Patients with AML with Profound Risk for Relapse and Death
Impact of NGS-based detection of FLT3 internal tandem duplication measurable residual disease on treatment outcome in newly diagnosed acute myeloid leukaemia
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma
Evidence for efficacy is based on the results from the MajesTEC-1 study
EMA Adopts Positive Opinion for Pemetrexed Baxter
It is a generic of Alimta which has been authorised in the EU since 2004
Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes in Overall Use Even in Immunotherapy Era
Rate of systemic anticancer treatment use within 30 days of death across all cancer types did not change in recent years